Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

At the heart of Eli Lilly's recent success and future prospects are its GLP-1 receptor agonists, Mounjaro (tirzepatide) for diabetes and Zepbound (tirzepatide) for obesity. These drugs have shown ...

Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales ...

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...

Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2 Eli Lillys CEO updates on drug trials amid mixed ...